Tocilizumab (Actemra and RoActemra) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) used as an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis. Interleukin 6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Link to this comment:
All Comments (0)